Samsung Biologics Wins KRW835.7 Billion Biologics CMO Contract; Shares Jump 5%
Samsung Biologics (KRX:207940) secured a biologics contract manufacturing organization (CMO) contract from an undisclosed US-based pharmaceutical company, according to a Wednesday filing with the Korean Exchange.The contract, valued at 835.7 billion won, is valid until Dec. 31, 2031.Shares of Samsung Biologics added over 5% in recent trade on Thursday.